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Abstract
Hypoglycaemia remains the most common metabolic adverse effect of insulin and sulfonylurea therapy in diabetes. Repeated
exposure to hypoglycaemia leads to a change in the symptom complex that characterises hypoglycaemia, culminating in a
clinical phenomenon referred to as impaired awareness of hypoglycaemia (IAH). IAH effects approximately 20–25% of people
with type 1 diabetes and increases the risk of severe hypoglycaemia. This review focuses on the mechanisms that are responsible
for the much higher frequency of hypoglycaemia in people with diabetes compared with those without, and subsequently how
repeated exposure to hypoglycaemia leads to the development of IAH. The mechanisms that result in IAH development are
incompletely understood and likely to reflect changes in multiple aspects of the counterregulatory response to hypoglycaemia,
from adaptations within glucose and non-glucose-sensing cells to changes in the integrative networks that govern glucose
homeostasis. Finally, we propose that the general process that incorporates many of these changes and results in IAH following
recurrent hypoglycaemia is a form of adaptive memory called ‘habituation’.
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Abbreviations
CRR Counterregulatory response
GABA γ-Aminobutyric acid
IAH Impaired awareness of hypoglycaemia
KATP ATP-sensitive potassium channel
VMH Ventromedial hypothalamus
The clinical importance of impaired
hypoglycaemia awareness
The characteristic symptom complex that alerts an individual
to hypoglycaemia is well described and is broadly represented
by three distinct symptom clusters, namely ‘autonomic’ (e.g.
sweating, palpitations), ‘neuroglycopaenic’ (e.g. confusion,
drowsiness) or ‘general malaise’ (e.g. headache, nausea) [1].
It is also widely reported that this hypoglycaemia symptom
complex varies considerably both between individuals and for
any given individual over the time course of their disease. For
some indiv idua ls , the symptomat ic response to
hypoglycaemia changes markedly such that hypoglycaemia
symptoms are not triggered until glucose levels are very low
and often occurring after cognitive function is impaired. This
is referred to as impaired awareness of hypoglycaemia (IAH),
defined as ‘a diminished ability to perceive the onset of acute
hypoglycaemia’ [2]. It is not a condition that is either present
or absent in an individual but reflects a continuum in which
differing degrees of IAH can occur and can vary over time.
IAH affects 20–25% of all people with type 1 diabetes, and as
much as 50% of those who have experienced severe
hypoglycaemia. Worryingly, the incidence of IAH has not
changed in the last two to three decades, even with the intro-
duction of insulin analogues and improved insulin delivery
systems [3]. The important clinical consequence of this is that,
in type 1 diabetes, IAH results in a six- to eightfold increased
risk for severe hypoglycaemia (defined as the need for
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external assistance to recover) [3, 4], which has a well-
recognised impact on morbidity and mortality in those with
type 1 diabetes [5] and places a significant psychosocial bur-
den on family members involved with their care [6]. IAH also
occurs in type 2 diabetes, affecting up to 10% of patients with
insulin-treated type 2 diabetes and markedly increasing risk of
severe hypoglycaemia [7].
In this review and the accompanying reviews by Iqbal and
Heller [8] and Choudhary and Amiel [9], we outline our cur-
rent understanding of why people with type 1 and long-
duration type 2 diabetes develop IAH and consider the options
that are currently available to prevent IAH or restore
hypoglycaemia awareness. Specifically, in this review, we
briefly outline the principal reasons why people with diabetes
are prone to hypoglycaemia and discuss the mechanisms that
may contribute to the development of IAH. We also propose
the hypothesis that IAH may result from a special form of
adaptive memory called ‘habituation’.
Why do people with diabetes develop
hypoglycaemia?
Although hypoglycaemia can occur in people without diabe-
tes (e.g. ‘reactive hypoglycaemia’), it is not common and, with
the exception of hypoglycaemia occurring during severe sep-
sis or malnutrition, it is not usually severe or of potential
pathological consequence. As a fuel, glucose is so fundamen-
tal to the survival of an organism that multiple systems are in
play to ensure that a continuous supply of glucose is provided
to the tissues of the body. These systems act in concert to
ensure that glucose utilisation by the brain, liver, muscle and
adipose tissue (white and brown), and glucose production and
release into the blood stream by the liver and kidney, are
tightly regulated. It seems highly likely that these systems
do not exist in isolation but form parts of a highly integrated
network designed both tomonitor overall blood nutrient levels
as well as fuel stores, and to direct fuels where and when
needed to specific tissues. For instance, a liver–brain axis that
is responsive to liver glycogen content was recently demon-
strated to modulate the counterregulatory response (CRR) to
insulin-induced hypoglycaemia [10]. Readers are referred to
an excellent review by Watts and Donovan, which elegantly
describes how the glucose-sensing network is structured very
much like a classical sensory–motor neural circuit with glu-
cose as an internally sensed stimulus and the CRR as the
motor output [11]. Brainstem and forebrain integrative
centres then serve to coordinate signals for multiple peripheral
and central outputs to ensure that glucose homeostasis is
maintained [11].
In type 1 diabetes (and, to some degree, type 2 diabetes),
hypoglycaemia is, by contrast, relatively common. There are
three principal abnormalities that underlie this propensity to
hypoglycaemia: (1) failure to clear circulating insulin during
hypoglycaemia; (2) loss of normal pancreatic alpha cell re-
sponses; and (3) lower glucose threshold for release of
counterregulatory hormones. Generally, the first two defects
explain why low glucose levels develop more frequently in
people with type 1 and type 2 diabetes in comparison with
people without diabetes, while the third major defect
(discussed in more detail in the next section) explains why a
subset of people with type 1 and type 2 diabetes may be even
more prone to hypoglycaemia and will occasionally suffer
severe hypoglycaemia.
The CRR is initiated when glucose levels fall beneath the
normal range and is designed to restore normal glucose ho-
meostasis. It encompasses hormonal, symptomatic and behav-
ioural responses. In people without diabetes, the first response
to a decline in blood glucose is a reduction in insulin secretion
that begins while plasma glucose concentration is still in the
physiological range (~4.4 mmol/l) [12]. In contrast, insulin
release from an unregulated subcutaneous depot in type 1
diabetes and/or the continued action of sulfonylureas in a
non-glucose dependent manner in type 2 diabetes means that
systemic insulin levels remain relatively high during
hypoglycaemia in diabetes. This is the first of the CRR de-
fects, namely the failure to clear (dissipate) insulin from sys-
temic circulation during hypoglycaemia. Relative insulin ex-
cess increases glucose uptake and suppresses hepatic glucose
production despite development of hypoglycaemia, and also
acts peripherally to limit lipolysis and the delivery of
gluconeogenic substrates to the liver. The overall effect is to
increase glucose uptake by tissues and reduce its production,
compounding any glucose-lowering stimulus.
The second major CRR defect is loss of physiological glu-
cagon secretion, which is profound in type 1 diabetes [13] but
also present in longer-duration type 2 diabetes [14]. The pan-
creatic beta and alpha cell react in a synchronous way to
changes in blood glucose levels (to which they are exposed)
and the resulting insulin:glucagon ratio in the portal venous
system is the major determinant, under most circumstances, of
hepatic glucose production. In people without diabetes, devel-
oping hypoglycaemia leads to the suppression of endogenous
insulin secretion (insulin ‘switch-off’) and a parallel rise in
glucagon release from the pancreatic alpha cell .
Paradoxically, by year 5 of disease duration in type 1 diabetes
[13, 15] and in long-duration, reduced C-peptide type 2 dia-
betes [14], glucagon secretion during hypoglycaemia is mark-
edly impaired. There is also a small, paradoxical increase in
glucagon release in the postprandial state [16]. The reason
why physiological alpha cell glucagon secretion is reversed
in diabetes is currently unknown. The earlier and more pro-
found effect in type 1 diabetes and the association with C-
peptide levels suggest loss of regulatory beta cell signals, such
as zinc, insulin or γ-aminobutyric acid (GABA) [17], but
direct effects of glucose [17] or paracrine signals, such as basal
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hypersecretion of somatostatin, may also explain the loss of
physiological glucagon [18]. Intriguingly, there has been re-
cent interest in the role of the pancreatic delta cell, and in
particular its major exocrine product, somatostatin, in this loss
of normal glucagon regulation and this has led to the proposal
that type 1 diabetes should perhaps be considered a disease of
beta, alpha and delta cells [19]. In addition, the difference in
glucose thresholds for insulin suppression (~4.4 mmol/l) and
glucagon activation (~3.8 mmol/l) suggest a potential role for
a central neurally mediated signal [17, 20, 21] in contributing
to this defect. This reversal of normal pancreatic beta and
alpha cell physiological responses to a reduction in glucose
is the secondmajor underlying reason for people with diabetes
being so much more prone to more profound hypoglycaemia
than those without diabetes (Fig. 1).
The third major CRR defect in type 1 and 2 diabetes is ob-
served in individuals with IAH. Characteristic features include a
higher threshold (lower glucose) for release of counterregulatory
hormone and symptom responses to experimentally-induced
hypoglycaemia, as well as reduced magnitude of these responses
[22]. This is illustrated in Fig. 1, which shows that, when sub-
jected to an identical glucose-lowering stimulus (a constant low-
dose insulin infusion), participants with type 1 diabetes who had
undergone 2–6months of intensive insulin therapy [resulting in a
change in HbA1c from 81 ± 12 mmol/mol (9.6 ± 1.1%) to 54 ±
8 mmol/mol (7.1 ± −0.7%] demonstrated markedly suppressed
counterregulatory hormonal and symptomatic responses to
hypoglycaemia compared with baseline. This resulted in far
more profound and prolonged hypoglycaemia [23].
Importantly, for individuals with suppressed CRRs, the glucose
level at which symptomatic awareness of hypoglycaemia occurs
is very low (usually <3.0 mmol/l) and at a point where cognitive
dysfunction can be detected (generally <2.8 mmol/l). The prin-
cipal symptoms of hypoglycaemia also change and are predom-
inantly neuroglycopaenic in nature. This reduced ability to detect
hypoglycaemia is referred to as IAH and, when more profound,
as hypoglycaemia unawareness. The main cause of this third
counterregulatory defect is considered to be prior exposure to
hypoglycaemia itself. Long duration of diabetes is also a risk
factor for IAH, but it is not clear whether this is a result of
recurrent, often silent hypoglycaemia, chronic hyperglycaemia
or microvascular disease directly affecting glucose-sensing ele-
ments. Because most of the research has examined the effect of
recurrent hypoglycaemia, this review will focus on this area.
Why do people with diabetes develop IAH?
A series of human clamp studies in the 1990s demonstrated
that prior hypoglycaemia in individuals with [24] or without
type 1 diabetes [25] is sufficient to significantly impair CRR
to hypoglycaemia that was induced the following day. Similar
responses to recurrent hypoglycaemia have been demonstrat-
ed in the rat [26] and mouse [27], indicating a highly con-
served response to repeated glucose deprivation. In summary,
repeated hypoglycaemia in diabetes leads to a progressive
reduction in the CRR, which eventually results in IAH and a
paradoxica l increased r i sk of severe , d isab l ing
hypoglycaemia. We will now consider the mechanisms that
may underpin this third CRR defect.
While recurrent hypoglycaemia is recognised as the prima-
ry risk factor leading to the development of IAH, the under-
lying mechanism(s) responsible for this remain less well un-
derstood. There is an extensive literature that has examined
this question and Fig. 2 illustrates potential mechanisms that
may contribute to the development of IAH. It is important to
note that this figure shows the relationship and communica-
tion between astrocytes and neurons to illustrate these con-
cepts, but that this by no means excludes contributory roles
for peripheral glucose-sensing systems, such as the
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Fig. 1 Counterregulatory failure in type 1 diabetes. Glucose profiles that
might develop following exposure to a constant low-dose insulin infusion
(1.3 U/h) in people with and without type 1 diabetes. Insulin infusion in
people without diabetes (purple circles) leads to an initial fall in glucose
before a CRR is triggered, resulting in glucose recovery towards baseline
levels. In comparison, in people with conventionally treated type 1 dia-
betes (orange circles), glucose will fall further when exposed to the same
insulin infusion and recovery will be impaired, mainly owing to a com-
bination of relative hyperinsulinaemia and loss of a significant glucagon
CRR. In contrast, following intensive insulin therapy (green circles) and
exposure to recurrent hypoglycaemia, glucose levels are expected to fall
much further and glucose recovery is markedly impaired.
Figure generated based on data in [23]. This figure is available as part
of a downloadable slideset
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portomesenteric vein sensors, or for peripheral organs, such as
the adrenal gland, in the development of IAH. Hypoglycaemia
represents profound cellular stress and, so, it is highly likely
that multiple cell types will respond to this challenge at some
level. As noted in Fig. 2, potential overall mechanisms that
may underpin the development of IAH include changes in
glucose and/or alternate fuel transport, or fuel storage, changes
in the intracellular metabolism of glucose and transduction of
the energy signal into altered neuronal firing rates, changes in
intracellular communication via autocrine, paracrine or endo-
crine signals or changes in neurotransmitter release. There is
limited scope for discussing these in detail but the following
section will outline some of the work that has been carried out
in these areas and refer the reader to recent, more specific
review articles.
The initial focus of investigators was to determine if recur-
rent hypoglycaemia resulted in an increase in glucose and/or
alternate fuel transport, or fuel storage. Certainly, studies in
rodent models and humans show an increase in the capacity to
transport glucose or alternate fuels through the blood–brain
barrier and into neurons and astrocytes [5, 28], as well as an
increase in whole brain glucose uptake after prolonged
hypoglycaemia [29]. Similarly, it was previously suggested
there may be an increased capacity to store glycogen in the
brain, providing a more readily accessible fuel source during
subsequent hypoglycaemia [5, 28]. However, many of these
studies were conducted in people or rodents without type 1
diabetes. More recent work suggests no increase in cerebral
glucose metabolism during hypoglycaemia in people with
type 1 diabetes and IAH [30] and no increase in brain glyco-
gen stores [31]. Moreover, compared with control animals,
detailed tracer studies in rodents indicate that, after recurrent
hypoglycaemia, neuronal glucose metabolism is actually de-
creased during subsequent hypoglycaemia [32]. In summary,
these studies suggest that recurrent hypoglycaemia leads to an
increased capacity of the human brain to use glucose and
alternate fuels, but it is not clear exactly how or where that
fuel is being used or whether this is ordinarily operative under
conditions of hyperinsulinaemic hypoglycaemia (for detailed
review, see [28]).
Alternatively, it is possible that prior hypoglycaemia in-
creases the capacity of the cell (neuron) to metabolise glucose,
generating more ATP for any given glucose level, which
would directly modulate ATP-sensitive potassium (KATP)
channels and shift thresholds for glucose-sensing neuron acti-
vation. Certainly, recurrent hypoglycaemia increases the ac-
tivity of neuronal glucokinase [33], the key first committed
step in glucose metabolism in the cell, while pharmacological
or genetic manipulation of neuronal glucokinase directly mod-
ulates the CRR [22]. Similarly, genetic manipulation of
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Fig. 2 Potential mechanisms underlying the development of IAH.
Multiple mechanisms may contribute to the development of IAH. The
figure shows the relationship and communication between astrocytes and
neurons to illustrate this, but peripheral glucose-sensing systems and pe-
ripheral organs may also contribute to the development of IAH. Proposed
mechanisms include: (1) an increase in glucose transport through glucose
transporters in the blood–brain barrier and/or on neurons/astrocytes; (2)
increased glycogen storage within astrocytes (‘glycogen
supercompensation’), leading to increased delivery of lactate to neurons;
(3) increased activity of glucokinase (GK) or reduced activity of AMPK,
leading to changes in neuronal firing rates, mediated by sulfonylurea
receptor-1 (SUR-1)-selective KATP channels; (4) changes in neurotrans-
mitter release, resulting in increased GABAergic tone (increased inhibi-
tory GABA release and/or reduced excitatory glutamate release); (5) re-
lease of gliotransmitters, such as cytokines and chemokines, that modu-
late neuronal firing rates; and (6) peripherally (or centrally) generated
signals, such as opiates/steroids and cytokines, that modulate neuronal
firing rates. This figure is available as part of a downloadable slideset
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hypothalamic AMP-activated protein kinase (AMPK), an in-
tracellular fuel gauge, also directly modulates CRRs [34].
However, as noted in the preceding paragraph, the evidence
in support of an overall change in glucose metabolism is at
best mixed and so, while targeting these critical glucose-
sensing kinases may be a useful approach to pharmacologi-
cally amplifying the CRR, it remains uncertain whether they
are actually responsible for the development of IAH [22]. An
alternative approach is to directly target the downstream me-
diator of the intracellular metabolic signal, namely the KATP
channel. Based on prior extensive animal research [22], this
was recently shown to be an effective approach for amplifying
the CRR to hypoglycaemia in individuals with long-standing
type 1 diabetes and reduced hypoglycaemia awareness [35] .
Neurotransmitters released from glucose-sensing neurons
within their neural circuit eventually activate the CRR.Within
key brain glucose-sensing sites, such as the ventromedial hy-
pothalamus (VMH), the excitatory neurotransmitter glutamate
[21] and the inhibitory neurotransmitter GABA [36] are con-
sidered to be critical to the CRR. Recurrent hypoglycaemia
leads to an increase in GABAergic inhibitory tone in the VMH
[36], which likely suppresses the excitatory glutamatergic out-
puts that drive the CRR [21]. GABAA receptor activation can
also suppress CRRs to subsequent hypoglycaemia in humans
[37]. This offers the therapeutic opportunity of targeting
GABA to augment CRRs in IAH. However, the difficulty
with progressing this latter work towards clinical trials of
hypoglycaemia prevention is that GABAergic neurons are
the major inhibitory neurons throughout the brain and so
blockade of GABA receptors, unless of very specific iso-
forms, is liable to have significant adverse effects. It is also
not clear from studies to date whether recurrent
hypoglycaemia directly acts on neurotransmitter production
and/or release or whether these changes are just secondary to
a different underlying mechanism.
More recently, there has been significant interest in discov-
ering how cytokine, purine, steroid, opiate, β2-adrenergic or
serotonergic signalling may play roles in the development of
IAH [22, 38–42]. These extracellular signals are able to mod-
ulate firing rates of glucose-sensing neurons. They may do so
by actions on neighbouring astrocytes, intraneuronal metabo-
lism, KATP channel activity, or through modulation of neuro-
transmitter release. They are secreted either in an autocrine
fashion from neurons, released by neighbouring astrocytes
or secreted from peripheral tissues, such as muscle. This
knowledge has been derived from laboratory-based research,
which has enabled proof-of-concept clinical trials. For in-
stance, the inhaled highly-selective β2-adrenoreceptor agonist
formoterol fumerate was shown to amplify the CRR to
hypoglycaemia in a small group of participants with type 1
diabetes [42], while oral dehydroepiandrostenedione
(DHEA), which has both anti-corticosteroid and anti-GABA
activity, blunted the suppressive effect of recurrent
hypoglycaemia on subsequent hypoglycaemia CRR in indi-
viduals without diabetes [39]. It is interesting that many of
these extracellular signals help coordinate the body’s response
to a wide variety of physiological stressors and play roles in
both amplifying the acute response to a given stressor and
initiating subsequent adaptive responses that are designed to
protect cells during subsequent exposure to that stressor.
Recent work from our own group, for instance, has shown
that pro- and anti-inflammatory cytokine release during
hypoglycaemia is modified significantly by prior exposure
to hypoglycaemia and also type 1 diabetes [43]. This raises
the possibility that the progressive suppression of CRR to
hypoglycaemia may result, at least at a cellular level, from a
series of adaptive responses to recurrent hypoglycaemia that is
initiated by a cell to ensure that it is better able to withstand
(tolerate) future exposure to a similar period of glucose dep-
rivation. This concept is consistent with findings from animal
models that show that prior hypoglycaemia actually limits the
impact of subsequent very severe hypoglycaemia on neuronal
survival [44], as discussed in more detail below.
Habituation and impaired hypoglycaemia
awareness
In a seminal review paper in the 1960s, Thompson and
Spencer sought to describe the properties of a form of learning
called ‘habituation’. Habituation is defined as a reduction in
the psychological, behavioural or physiological response to a
stimulus as a result of repeated or prolonged exposure.
Habituation is a form of adaptive learning and is usually seen
in the context of innate behaviours, presenting as a reduced
response to repeated external or internal stimuli [45, 46].
Habituation is now recognised to occur in virtually all or-
ganisms in response to a variety of stressful stimuli [46]. At a
biological level, habituation reflects a survival response where
cells adapt to repeated exposure to the physiological stressor
in order to develop greater tolerance of that specific stressor.
There are clear parallels between habituation and IAH, with
similar widespread effects of recurrent hypoglycaemia on
physiological (e.g. suppressed counterregulatory hormonal
and symptomatic responses), behavioural (e.g. reduced drive
to feed) and psychological (e.g. reduced anxiety) responses.
Thompson and Spencer [45] proposed nine principal features
of a habituated response (updated more recently by Rankin
et al. [46]). The first of these principles was: ‘Given that a
particular stimulus elicits a response, repeated applications
of the stimulus result in decreased response (habituation)…’.
This is a characteristic feature of hypoglycaemia, where re-
peated exposure to hypoglycaemia leads to decreased symp-
toms and CRRs to a subsequent episode [24, 25]. Likewise,
recovery of CRR through hypoglycaemia avoidance [47] is in
keeping with the second characteristic of habituation; namely,
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‘if the stimulus [hypoglycaemia] is withheld, the response
[CRR] tends to recover over time (spontaneous recovery)’.
In fact, studies in rodent and human models of IAH have
reported findings consistent with six of the nine principles of
habituation proposed by Thompson and Spencer (for review
see [48]).
A further defining feature of a habituated response is that it
should be possible to acutely restore the response through
introduction of a novel, usually strong stimulus. This is a
process referred to as ‘dishabituation’. In a recent study from
the authors’ laboratory, introduction of a dishabituatory stim-
ulus was indeed shown to restore normal CRRs to
hypoglycaemia in a rodent model [49]. In this study, rodents
were subjected to recurrent episodes of insulin-induced
hypoglycaemia or saline control injections over a 4 week pe-
riod. Subsequently, the rats were exposed to either a low-
intensity exercise regimen on a treadmill or a burst of high-
intensity exercise (dishabituatory stimulus). The following
day, all animals underwent an equivalent hypoglycaemic stim-
ulus (hypoglycaemic clamp). As expected, CRRs were sup-
pressed in rodents exposed to 4 weeks of recurrent
hypoglycaemia; however, in the group of rodents who had
experienced recurrent hypoglycaemia followed by a single
episode of high-intensity exercise, the CRR was restored to
control levels (Fig. 3) [49]. This finding very much suggests
that IAH results from habituation and is a learned adaptive
response to repeated exposure to the same stimulus. This con-
cept remains hypothetical and requires further validation in
both laboratory-based in vitro and animal studies, and human
studies but does provide a basis for conceptualising the whole
organism response to recurrent hypoglycaemia. It may seem
paradoxical that the organism responds to repeated
hypoglycaemia by initiating an adaptive response that renders
it more susceptible to future hypoglycaemia, but we should
recognise that iatrogenic hypoglycaemia as a result of exoge-
nous insulin or sulfonylurea exposure, in the presence of an
added alpha cell glucagon secretory defect, creates a physio-
logical condition that we have not evolved to respond to,
namely profound hyperinsulinaemic hypoglycaemia.
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Fig. 3 Dishabituation with high-intensity exercise. Rodents were subject-
ed to recurrent episodes of insulin-induced hypoglycaemia or saline con-
trol injections over 4 weeks. Rats were then exposed to low-intensity or
high-intensity exercise, the latter being a dishabituatory stimulus.
Twenty-four hours later, animals underwent a hyperglycaemic clamp
and CRR variables were measured. (a) Plasma glucose during
hyperinsulinaemic–hypoglycaemic clamp study. (b) Glucose infusion
rates (GIR) required to maintain equivalent hypoglycaemia. (c) Plasma
adrenaline (epinephrine), and (d) glucagon responses during
hypoglycaemia. Control animals, white circles/bars; recurrently
hypoglycaemic (RH) animals exposed to low-intensity (LI) exercise, or-
ange squares/bars; RH animals exposed to high-intensity (HI) exercise,
green diamonds/bars. Values shown as mean ± SEM. *p < 0.05 vs con-
trol. Figure adapted from [49]. Material from this publication has been
used with the permission of ADA. Copyright and all rights reserved. This
figure is available as part of a downloadable slideset
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Conclusions
Hypoglycaemia remains a concern for people with type
1 and type 2 diabetes. In diabetes, hypoglycaemia re-
sults from profound disturbances in glucose homeostasis
and, in particular, the inability to ‘shut off’ exogenous
insulin delivery and loss of normal physiological regu-
lation of glucagon secretion. Recurrent hypoglycaemia
leads to further marked suppression of counterregulatory
hormonal and symptomatic responses to subsequent
hypoglycaemia, a clinical phenomenon referred to as
IAH. The mechanism(s) underlying the development of
IAH are incompletely understood but may, or are per-
haps likely, to involve multiple rather than single steps
in the generation of a CRR. These adaptations occur on
multiple levels, from within individual glucose and non-
glucose-sensing cells, all the way up to the integrative
networks that govern glucose homeostasis. Conceptually,
IAH may result from habituation (a special form of
adaptive memory) to recurrent hypoglycaemia. This
form of adaptation to repeated hypoglycaemia is aimed
at inducing greater cellular tolerance of subsequent
hypoglycaemia, but in fact increases susceptibility to
future hypoglycaemia.
By increasing our understanding of the mechanisms
that lead to the development of IAH, we are better placed
to consider how to approach the management of this con-
dition. For instance, to resolve the problem of insulin
dissipation, we are now aware that more physiological-
and glucose-responsive insulin therapies are required.
Restoration of physiological glucagon secretion would al-
so be a major advance, but we must first obtain a clearer
idea of why this defect develops in diabetes. Finally, ha-
bituation is best treated by avoidance of the habituating
stimulus, namely hypoglycaemia, and this is currently
best achieved through structured education, as discussed
by Iqbal and Heller [8]. Further, for some individuals,
habituation leads to chronic behavioural change that may
require additional interventions, such as cognitive behav-
ioural therapy, to support hypoglycaemia avoidance strat-
egies, as discussed by Choudhary and Amiel [9]. In the
future, novel strategies such as dishabituation or pharma-
cological interventions may also be an option as part of
the package of care required to restore or reverse IAH.
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